This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
Other namesWAY-202196
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass279.27 g/mol g·mol−1
3D model (JSmol)

ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2][3][4][5][6] It possesses 78-fold selectivity for the ERβ over the ERα.[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.[2][7]

See also


  1. ^ a b R. E. Hubbard (2006). Structure-based Drug Discovery: An Overview. Royal Society of Chemistry. pp. 241–. ISBN 978-0-85404-351-4.
  2. ^ a b [][permanent dead link]
  3. ^ Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 52–. ISBN 978-1-4816-8771-3.
  4. ^ Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 66–. ISBN 978-3-527-62330-3.
  5. ^ Mewshaw RE, Edsall RJ, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005). "ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity". J. Med. Chem. 48 (12): 3953–79. doi:10.1021/jm058173s. PMID 15943471.
  6. ^ Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Harris HA (2006). "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock". Crit. Care Med. 34 (8): 2188–93. doi:10.1097/01.CCM.0000227173.13497.56. PMID 16755255.
  7. ^ Jean-Louis Vincent (8 December 2007). Yearbook of Intensive Care and Emergency Medicine 2007. Springer Science & Business Media. pp. 891–. ISBN 978-3-540-49433-1.

External links